Who is sponsoring NCT06767904?

NCT06767904 is sponsored by Sissel Kronborg-White.

What drugs are being tested in NCT06767904?

Interventions in NCT06767904: Continous Oxygen by Bottles, Demand oxygen by Portable Concentrator.

What condition does NCT06767904 study?

NCT06767904 studies Interstitial Lung Disease, Chronic Obstructive Pulmonary Disease.

Is NCT06767904 still recruiting?

NCT06767904 is currently not yet recruiting. Last updated 17 January 2025.

Last reviewed 2025-01-17 · How we verify

NCT06767904: OXYODE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Continuous Versus Demand-Based Oxygen in Patients With Fibrotic Interstitial Lung Disease and Chronic Obstructive Pulmonary Disease

Not yet recruiting NA Last updated 17 January 2025

What this trial tests

NA trial testing Continous Oxygen by Bottles in Interstitial Lung Disease in 60 participants. Not yet recruiting.

Timeline

1 March 2025

Primary endpoint
31 August 2026

28 February 2027

Quick facts

Lead sponsor	Sissel Kronborg-White
Phase	NA
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	single
Primary purpose	treatment
Enrollment	60
Start date	1 March 2025
Primary completion	31 August 2026
Estimated completion	28 February 2027

Drugs / interventions tested

Continous Oxygen by Bottles
Demand oxygen by Portable Concentrator

Conditions studied

Interstitial Lung Disease — all drugs for Interstitial Lung Disease →
Chronic Obstructive Pulmonary Disease — all drugs for Chronic Obstructive Pulmonary Disease →

Sponsor

Sissel Kronborg-White

Who can join

18 and older, any sex, with Interstitial Lung Disease or Chronic Obstructive Pulmonary Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this randomised clinical trial is to compare the efficacy of exertional oxygen delivery by continous versus demand-based flow systems in patients with fibrotic Interstitial lung disease and chronic obstructive pulmonary disease . The main questions it aim to answer: Is there a difference in lowest oxygen saturation? Is there a difference in saturation: time below \<90%, pulse rate, distance and patient preferences ? It is a cross over study, so all patients will test both methods. Participants will perform 2 6-minute walk tests with the two different oxygen delivery systems.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Comparing the efficacy of exertional oxygen delivery by continuous versus demand-based flow systems during 6-minute walk test in patients with fibrotic interstitial lung disease and COPD in a hospital setting (OXYCODE): a protocol for a randomised trial.
Kronborg-White S, Jensen JH, Bendstrup E, Prior TS. · · 2025 · PMID 40379312 · DOI 10.1136/bmjopen-2025-099664

Verify or expand the search:

Other recruiting trials for Interstitial Lung Disease

Currently open trials in the same condition.

NCT07451977 — Effects of Oxygen Supplementation During the 6-Minute Walk Test in Chronic Respiratory Failure or Exertional Hypoxemia · NA · recruiting
NCT07254338 — Exploration of Metabolome in Patients With Interstitial Lung Disease and Pulmonary Hypertension With or Without Specific · recruiting
NCT07269262 — SUPPORT-T in Patients With Progressive Pulmonary Fibrosis and Their Caregivers · NA · recruiting
NCT07179380 — Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension · Phase 3 · recruiting
NCT07323732 — A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Diseas · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06767904 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sissel Kronborg-White
Last refreshed: 17 January 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06767904.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing